- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05095298
Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
February 12, 2022 updated by: Wen-hong Zhang, Huashan Hospital
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group.
Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention.
Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Ditan Hospital Capital Medical University
-
-
Jingan
-
Shanghai, Jingan, China, 200041
- Huashan Hospital affiliated to Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥ 18 years old,
- Through asking medical history and physical examination, the investigator judged that the health condition is good: the chronic disease is stable and there is no change within 3 months of medication;
- has been completed 2 doses of Covid-19 Inactivated vaccine 4-8 months ago;
- Female participants of childbearing age who were not breast-feeding or pregnant (negative blood pregnancy test), and had no family planning in the first 3 months after enrollment and took effective contraceptive measures. Take effective contraceptive measures within 2 weeks before inclusion;
- Volunteered to receive the third dose of vaccine.And during the entire follow-up research period, be able and willing to complete the entire prescribed research plan; Have the ability to self-understand research procedures, informed consent & voluntarily sign informed consent, and be able to comply with the requirements of the plan
Exclusion Criteria:
- RT-qPCR detects active SARS-Cov-2 infection;
- a history of COVID-19, SARS, MERS infection (self-report, on-site inquiry);
- a high-risk factor for COVID-19 infection:
- a history of close contact with people infected with the new coronavirus, a history of living in high-risk areas, and a history of contact with patients with fever or respiratory symptoms in high-risk areas or abroad.
- Fever, dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, dyspnea, etc. 7 days before enrollment;
- receiving COVID-19 booster vaccination;
- allergic to the active ingredients of the SARS-CoV-2 vaccine, any of the inactive ingredients, the substances used in the production process, or those who have had allergies during previous vaccination of similar vaccines;
- those who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioedema, respiratory Difficulties, urticaria, angioedema or abdominal pain);
- body temperature >37.0℃ before vaccination;
- blood pregnancy test positive;
- with uncontrolled epilepsy and other serious neurological diseases (such as transmissive myelitis, Guillain-Barre syndrome) , Demyelinating diseases, etc.), or have a history or family history of encephalopathy or mental disease;
- severe liver and kidney disease, uncontrollable hypertension (systolic blood pressure ≥180 mmHg, diastolic blood pressure ≥100 mmHg), diabetic complications, Malignant tumors, various acute diseases or acute attacks of chronic diseases;
- diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
- receiving anti-tuberculosis treatment;
- a history of coagulopathy ( Such as coagulation factor deficiency, coagulation disease) within 3 months of subjects receiving immunotherapy or inhibitor therapy (continuous oral or infusion for more than 14 days), or after 3 months of hormone therapy, the average daily dose is ≥20mg/day (Prednisone);
- Receiving live attenuated vaccine within 1 month before this vaccination, other vaccines within 14 days before this vaccination;
- Receiving other research drugs within 3 months before vaccination; participating in other research vaccines Or subjects in clinical trials of research drugs;
- other conditions that the investigator judges are not suitable for this clinical trial;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group
Participants volunteered not to receive the third dose of vaccine, and agreed to be followed-up for 1 year
|
|
Experimental: Inactivated Vaccine Group
Participants volunteered to receive the third dose of inactivated vaccine
|
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group.
Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention.
Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
|
Experimental: Recombinant subunit protein vaccine
Participants volunteered to receive the third dose of subunit protein vaccine
|
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group.
Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention.
Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
|
Experimental: mRNA vaccine Group
Participants volunteered to receive the third dose of mRNA vaccine ( To be enrolled, the vaccine has not been approved in China)
|
It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group.
Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention.
Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
Time Frame: Day 28
|
Observe the 28th day of the subjects' pseudovirus neutralizing antibody geometric mean titers (GMTs) and mean geometric titers fold growth (GMFR) changes
|
Day 28
|
Reactogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines
Time Frame: Day 28
|
All solicited and non-solicited adverse events within 28 days.
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The seropositive rate of neutralizing antibodies
Time Frame: 3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
|
The seropositive rate of neutralizing antibodies after third vaccination shots
|
3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
|
GMT of neutralizing antibodies
Time Frame: 3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
|
GMT of neutralizing antibodies after third vaccination shots
|
3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
|
GMFR of neutralizing antibodies
Time Frame: 3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
|
GMFR of neutralizing antibodies after third vaccination shots
|
3 days/14 days/28days/45days/60 days/90 days/180 days/365 days
|
severe adverse events and adverse events of special interest
Time Frame: up to 1 year
|
severe adverse events and adverse events of special interest
|
up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2021
Primary Completion (Anticipated)
March 15, 2022
Study Completion (Anticipated)
August 1, 2022
Study Registration Dates
First Submitted
October 2, 2021
First Submitted That Met QC Criteria
October 15, 2021
First Posted (Actual)
October 27, 2021
Study Record Updates
Last Update Posted (Actual)
March 2, 2022
Last Update Submitted That Met QC Criteria
February 12, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- BOOST
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Vaccine, COVID19
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Robert Leet...Active, not recruitingMultiple Sclerosis | Autoimmune Blistering Disease | B-Cell DeficiencyUnited States
-
University of Roma La SapienzaIstituto Superiore di SanitàRecruitingHealth Care Utilization | Health Care Associated InfectionItaly
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...CompletedCOVID-19 | Vaccine Adverse Reaction | Vaccine Reaction | Liver Transplant; Complications | Lung Transplant; Complications | Vaccine Response Impaired | VaccinationItaly
-
Health Institutes of TurkeyTC Erciyes University; Mene Research; Kocak FarmaNot yet recruiting
-
University of ManitobaPublic Health Agency of Canada (PHAC); Cadham Provincial LabNot yet recruiting
-
Providence Therapeutics Holdings Inc.Completed
-
Vaxine Pty LtdCentral Adelaide Local Health Network IncorporatedCompleted
-
Centre Hospitalier Régional Metz-ThionvilleRecruitingCOVID-19 | Quality of Life | Cognitive Impairment | Posttraumatic Stress Disorder | Social BehaviorFrance
-
Slavko RoganRecruiting